DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?

DaVita HealthCare (DVA), a leading U.S. dialysis service provider, is positioned as a notable growth opportunity, currently holding a Zacks #3 (Hold) Rank with 'A' ratings for both its VGM and Growth Style Scores. The company forecasts 12.9% year-over-year earnings growth for the current fiscal year, bolstered by two recent upward analyst revisions that increased the FY2025 consensus earnings estimate by $0.17 to $10.93 per share, alongside a consistent average earnings surprise of +4.7%. This profile suggests DVA warrants consideration for growth-oriented investors' shortlists.

Analysis

DaVita Inc. (DVA) presents a compelling growth profile tempered by a neutral overall rating, according to the provided Zacks analysis. The company receives top-tier 'A' ratings for both its Growth Style Score and its composite VGM Score, indicating strong underlying fundamentals. This is substantiated by a forecast for 12.9% year-over-year earnings growth in the current fiscal year and a consistent history of positive earnings surprises, averaging +4.7%. Furthermore, analyst sentiment appears to be improving, with two upward earnings estimate revisions for fiscal 2025 within the last 60 days, pushing the consensus estimate up by $0.17 to $10.93 per share. However, these positive growth indicators are juxtaposed with a Zacks Rank of #3 (Hold), which, while not negative, suggests the absence of a strong, immediate catalyst for outperformance compared to stocks with #1 (Strong Buy) or #2 (Buy) ratings. The analysis frames DVA as a stock with significant upside potential for growth investors, provided its strong style scores are considered in conjunction with its neutral rank.

Key Decisions for Investors

• Growth-oriented investors should consider adding DVA to their watchlist, given its 'A' rated Growth Score, double-digit earnings growth forecast, and positive momentum in analyst estimate revisions.
• The neutral Zacks #3 (Hold) rank warrants a degree of caution; investors may want to monitor for a potential upgrade to a #1 or #2 rank, which would provide a stronger buy signal according to this specific methodology.
• Given the positive fundamental indicators, investors could evaluate DVA's current valuation against its 12.9% earnings growth projection to determine if an attractive entry point exists, despite the lack of a top-tier buy rating.